Neurocrine UK Limited
Neurocrine Biosciences is dedicated to discovering and developing life-changing treatments for neurological, neuroendocrine, and neuropsychiatric disorders. With over 30 years of scientific research, the company focuses on unmet medical needs, offering FDA-approved treatments and a robust pipeline of investigational candidates. Their mission is to relieve suffering for people with great needs through brave science, innovation, and collaboration.
Industries
Nr. of Employees
Very Large (1000+)
Neurocrine UK Limited
San Diego, California, United States, North America
Products
Oral VMAT2 inhibitor therapies for movement disorders (FDA-approved indications)
Orally administered vesicular monoamine transporter 2 (VMAT2) inhibitors developed and approved for certain movement disorder indications, with ongoing study in additional patient populations.
Oral CRF1 receptor antagonist for congenital adrenal hyperplasia (FDA-approved)
An orally administered corticotropin‑releasing factor type 1 (CRF1) receptor antagonist approved for management of classic congenital adrenal hyperplasia, with long-term safety studies described.
Out-licensed hormonal therapy discovered through early development
Hormonal therapy programs discovered through early-phase development and subsequently out‑licensed to commercialization partners; the company retains royalty interests under collaboration agreements.
Oral VMAT2 inhibitor therapies for movement disorders (FDA-approved indications)
Orally administered vesicular monoamine transporter 2 (VMAT2) inhibitors developed and approved for certain movement disorder indications, with ongoing study in additional patient populations.
Oral CRF1 receptor antagonist for congenital adrenal hyperplasia (FDA-approved)
An orally administered corticotropin‑releasing factor type 1 (CRF1) receptor antagonist approved for management of classic congenital adrenal hyperplasia, with long-term safety studies described.
Out-licensed hormonal therapy discovered through early development
Hormonal therapy programs discovered through early-phase development and subsequently out‑licensed to commercialization partners; the company retains royalty interests under collaboration agreements.
Services
Clinical development and trial conduct
Planning and execution of Phase 1–3 clinical trials, including registrational programs and long-term safety studies.
Expanded access program (EAP) management
Case-by-case review and administration of expanded access requests for investigational medicines when enrollment in clinical trials is not possible.
Medical grants and patient organization funding
Provision of limited financial support for patient advocacy groups focused on specified therapeutic areas via an online portal.
Licensing and commercialization partnerships
Development, negotiation, and management of licensing agreements and regional commercialization collaborations, including royalty arrangements.
Clinical development and trial conduct
Planning and execution of Phase 1–3 clinical trials, including registrational programs and long-term safety studies.
Expanded access program (EAP) management
Case-by-case review and administration of expanded access requests for investigational medicines when enrollment in clinical trials is not possible.
Medical grants and patient organization funding
Provision of limited financial support for patient advocacy groups focused on specified therapeutic areas via an online portal.
Licensing and commercialization partnerships
Development, negotiation, and management of licensing agreements and regional commercialization collaborations, including royalty arrangements.
Expertise Areas
- Clinical trial management
- Neurology drug discovery
- Neuropsychiatry drug development
- Neuroendocrinology drug development
Key Technologies
- Small-molecule therapeutics
- Peptide therapeutics
- Protein and antibody modalities
- Gene therapy platforms